Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris

ClinicalTrials.gov ID: NCT01631474

Public ClinicalTrials.gov record NCT01631474. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 12, 2026, 8:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

CB-03-01 is being developed for the topical treatment of acne vulgaris, an androgen-dependent skin disorder. The purpose of this study is to compare the safety and efficacy of multiple concentrations of CB-03-01 to vehicle in the treatment of acne vulgaris.

Study identification

NCT ID
NCT01631474
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Enrollment
363 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2012
Primary completion
Jan 31, 2014
Completion
Jan 31, 2014
Last update posted
Nov 15, 2020

2012 – 2014

United States locations

U.S. sites
13
U.S. states
10
U.S. cities
12
Facility City State ZIP Site status
Dermatology Research Associates Los Angeles California 90045
Therapeutics Clinical Research San Diego California 92123
University Clinical Trials San Diego California 92123
International Clinical Research - US, LLC Sanford Florida
Gwinnett Clinical Research Center, Inc. Snellville Georgia 30078
Altman Dermatology Associates Arlington Heights Illinois 60005
Indiana Clinical Trials Center Plainfield Indiana 46168
Marina I. Peredo, M.D., PC Smithtown New York
Penn State Milton S. Hershey Medical Center - Dept. of Dermatology Hershey Pennsylvania 17033
Clinical Partners, LLC Johnston Rhode Island
J & S Studies College Station Texas 77845
UT Houston Health Science Center Houston Texas 77030
Virginia Clinical Research Norfolk Virginia 23507

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01631474, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 15, 2020 · Synced Sep 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01631474 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →